WallStreetZenWallStreetZen

NASDAQ: ARWR
Arrowhead Pharmaceuticals Inc Stock

$27.24+1.74 (+6.82%)
Updated Jun 24, 2024
ARWR Price
$27.24
Fair Value Price
-$21.85
Market Cap
$3.38B
52 Week Low
$20.67
52 Week High
$39.83
P/E
-6.42x
P/B
6.99x
P/S
99.4x
PEG
N/A
Dividend Yield
N/A
Revenue
$35.47M
Earnings
-$470.79M
Gross Margin
100%
Operating Margin
-1,263.79%
Profit Margin
-1,327.2%
Debt to Equity
0.95
Operating Cash Flow
-$257M
Beta
1.34
Next Earnings
Aug 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ARWR Overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ARWR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ARWR ($27.24) is overvalued by 224.65% relative to our estimate of its Fair Value price of -$21.85 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ARWR ($27.24) is not significantly undervalued (224.65%) relative to our estimate of its Fair Value price of -$21.85 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ARWR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ARWR due diligence checks available for Premium users.

Be the first to know about important ARWR news, forecast changes, insider trades & much more!

ARWR News

Valuation

ARWR fair value

Fair Value of ARWR stock based on Discounted Cash Flow (DCF)
Price
$27.24
Fair Value
-$21.85
Undervalued by
224.65%
ARWR ($27.24) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ARWR ($27.24) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ARWR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ARWR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-6.42x
Industry
-6.96x
Market
30.03x

ARWR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
6.99x
Industry
6.29x
ARWR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ARWR's financial health

Profit margin

Revenue
$0.0
Net Income
-$125.3M
Profit Margin
0%
ARWR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ARWR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$955.2M
Liabilities
$459.7M
Debt to equity
0.95
ARWR's short-term assets ($541.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARWR's short-term assets ($541.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARWR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ARWR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$92.4M
Investing
-$268.9M
Financing
$430.8M
ARWR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ARWR vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ARWR$3.38B+6.82%-6.42x6.99x
MRUS$3.34B+3.77%-20.55x9.56x
RARE$3.28B-0.45%-4.96x23.36x
DNLI$3.27B+1.24%-24.63x2.24x
CORT$3.18B+1.83%26.60x5.81x

Arrowhead Pharmaceuticals Stock FAQ

What is Arrowhead Pharmaceuticals's quote symbol?

(NASDAQ: ARWR) Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol ARWR. Arrowhead Pharmaceuticals stock quotes can also be displayed as NASDAQ: ARWR.

If you're new to stock investing, here's how to buy Arrowhead Pharmaceuticals stock.

What is the 52 week high and low for Arrowhead Pharmaceuticals (NASDAQ: ARWR)?

(NASDAQ: ARWR) Arrowhead Pharmaceuticals's 52-week high was $39.83, and its 52-week low was $20.67. It is currently -31.61% from its 52-week high and 31.79% from its 52-week low.

How much is Arrowhead Pharmaceuticals stock worth today?

(NASDAQ: ARWR) Arrowhead Pharmaceuticals currently has 124,200,230 outstanding shares. With Arrowhead Pharmaceuticals stock trading at $27.24 per share, the total value of Arrowhead Pharmaceuticals stock (market capitalization) is $3.38B.

Arrowhead Pharmaceuticals stock was originally listed at a price of $32.50 in Dec 31, 1997. If you had invested in Arrowhead Pharmaceuticals stock at $32.50, your return over the last 26 years would have been -16.18%, for an annualized return of -0.68% (not including any dividends or dividend reinvestments).

How much is Arrowhead Pharmaceuticals's stock price per share?

(NASDAQ: ARWR) Arrowhead Pharmaceuticals stock price per share is $27.24 today (as of Jun 24, 2024).

What is Arrowhead Pharmaceuticals's Market Cap?

(NASDAQ: ARWR) Arrowhead Pharmaceuticals's market cap is $3.38B, as of Jun 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Arrowhead Pharmaceuticals's market cap is calculated by multiplying ARWR's current stock price of $27.24 by ARWR's total outstanding shares of 124,200,230.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.